HOOKIPA Pharma (HOOKIPA Pharma) FCF Margin % : -157.23% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is HOOKIPA Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. HOOKIPA Pharma's Free Cash Flow for the three months ended in Dec. 2023 was $-11.65 Mil. HOOKIPA Pharma's Revenue for the three months ended in Dec. 2023 was $7.41 Mil. Therefore, HOOKIPA Pharma's FCF Margin % for the quarter that ended in Dec. 2023 was -157.23%.

As of today, HOOKIPA Pharma's current FCF Yield % is -69.79%.

The historical rank and industry rank for HOOKIPA Pharma's FCF Margin % or its related term are showing as below:

HOOK' s FCF Margin % Range Over the Past 10 Years
Min: -426.05 Med: -265.61 Max: -175.55
Current: -306.44

During the past 7 years, the highest FCF Margin % of HOOKIPA Pharma was -175.55%. The lowest was -426.05%. And the median was -265.61%.

HOOK's FCF Margin % is ranked worse than
59.4% of 1032 companies
in the Biotechnology industry
Industry Median: -148.935 vs HOOK: -306.44

HOOKIPA Pharma FCF Margin % Historical Data

The historical data trend for HOOKIPA Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HOOKIPA Pharma FCF Margin % Chart

HOOKIPA Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-366.19

-212.98

-426.05

-175.55

-306.44

HOOKIPA Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															160.17	-98.30	-738.26	-395.18	-157.23

Competitive Comparison of HOOKIPA Pharma's FCF Margin %

For the Biotechnology subindustry, HOOKIPA Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HOOKIPA Pharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where HOOKIPA Pharma's FCF Margin % falls into.

HOOKIPA Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

HOOKIPA Pharma's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-61.683	/	20.129
	=	-306.44 %

HOOKIPA Pharma's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-11.646	/	7.407
	=	-157.23 %

HOOKIPA Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of HOOKIPA Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

HOOKIPA Pharma (HOOKIPA Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HOOKIPA Pharma Inc (NAS:HOOK) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118

Website

https://www.hookipapharma.com

HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.

Executives

Reinhard Kandera	director, officer: Chief Financial Officer	C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., 14TH FLOOR, NEW YORK NY 10016
Jorn Aldag	director, officer: Chief Executive Officer	C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA 02210
Mary Theresa Coelho	director	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Katia Schlienger	officer: Chief Medical Officer	350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Malte Peters	director	TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Timothy P. Reilly	director	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10018
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404
Igor Matushansky	officer: Chief Medical Officer	C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Sofinnova Capital Vi Fcpr	10 percent owner	C/O SOFINNOVA PARTNERS, 17 RUE DE SURENE, PARIS XX 75008
Christine D. Baker	officer: Chief Business Officer	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Jean-charles Soria	director	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE SUITE 7240, NEW YORK NY 10118
Anders Lilja	officer: Sr. VP, Technical Development	C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., 14TH FLOOR, NEW YORK NY 10016
Klaus Orlinger	officer: Sr. VP, Research	C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Roman Necina	officer: Chief Technology Officer	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Forbion Capital Fund Ii Cooperatief U.a.	10 percent owner	C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016